Crossmark

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib

Crossref DOI link: https://doi.org/10.1186/s12885-018-5173-0

Published Online: 2018-12-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

da Fonseca, Leonardo Gomes http://orcid.org/0000-0002-0216-3618
Marta, Guilherme Nader

Braghiroli, Maria Ignez Freitas Melro

Chagas, Aline Lopes

Carrilho, Flair Jose

Hoff, Paulo Marcelo

Sabbaga, Jorge
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 31 August 2018

Accepted: 3 December 2018

First Online: 13 December 2018

Ethics approval and consent to participate

: The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.The Research Ethics Committee of <i>Faculdade de Medicina da Universidade de São Paulo</i> (FMUSP) approved the study protocol (protocol identification: NP1123/17).Consent to participate: this is a retrospective study and consent to participate was waived by the Research Ethics Committee of <i>Faculdade de Medicina da Universidade de São Paulo</i> (FMUSP).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.